Aurobindo Pharma News

Submission of proceedings of 37th Annual General meeting of the Company held on August 29, 2024.

The Company has received an order from the Deputy Commissioner, Punjagautta(ST) STU-1 of GST, Hyderabad.

Stocks to Buy Today: The Indian stock market is expected to consolidate on Thursday amid mixed global cues. Analysts suggest a broader trading range between 24,700 and 25,500 zones. Key stock recommendations include Granules India, Voltas, and Eicher Motors, among others. Traders are advised to look out for specific buy targets and stop losses.

Intimation of Investor meet

Intimation of loss of share certificates.

The New Jersey-based Aurobindo Pharma USA Inc initiated the Class 1 recall on July 11, it said. As per the US health regulator, a Class I recall pertains to defective products that can cause serious health problems. Similarly, a US-based subsidiary of Glenmark Pharmaceuticals is recalling 2,404 bottles of Indomethacin Extended-Release Capsules, produced at a Madhya Pradesh plant, due to "Failed Dissolution Specifications", USFDA said.

Submission of Certificate of Extinguishments 51,36,986 equity shares of Re. 1 each bought back under the Company''s Buyback offer.

The US Food and Drug Administration (USFDA) has issued a warning letter to Eugia Pharma Specialities, a subsidiary of Aurobindo Pharma, citing significant manufacturing issues at its Telangana plant. The USFDA's inspection from January 22 to February 2, 2024, revealed problems including inaccurate production and process simulation data, falsified environmental monitoring records, and incomplete batch production and control records.

The letter, issued on August 15, was later made public by the USFDA, which stated that there was failure to ensure the accuracy of data in records for both production and process simulations, i.e. media fills. Media fill is a microbiological test to help prevent contamination during drug production.

Submission of post buyback public announcement.

Aurobindo Pharma's China facility is set to start production in the next quarter, with full-scale output expected in the next fiscal year. The company plans to roll out small volumes in November-December, ramping up in January-March. Chief Financial Officer Santhanam Subramanian anticipates commercialisation in Q3 FY25 and volume production in FY26. The company is also progressing with Pen-G commercialization and aims for an EBITDA margin of 21-22%.

Submission of Transcript of Earning call on unaudited financial results of Q1 2024-25.

Aurobindo Pharma's subsidiary Eugia Pharma Specialities received a warning letter from the USFDA concerning its formulations manufacturing unit in Telangana. This followed an earlier inspection that resulted in an 'Official Action Indicated' status. Aurobindo affirmed that current US supplies are unaffected and emphasized their commitment to enhancing compliance with regulatory standards.

Intimation of receipt of Warning Letter from US FDA for Unit III of Eugia Pharma Specialities Limited, a wholly owned subsidiarity of the Company

Aurobindo Pharma is revisiting plans to sell a strategic stake in its injectable unit, Eugia Pharma Specialities, focusing on an IPO. Previously hampered by valuation issues with private equity, the process faces new hurdles due to USFDA observations. Eugia aims to reach $600 million in revenue this fiscal year. Regulatory issues at Unit-3 remain a concern.

Intimation of investor meet (Motilal Oswal) on 20.08.2024.

Intimation of investor meeting (IIFL Capital) on 21.08.2024.

Intimation of investor meet (IIFL Capital) on 20.08.2024.

Aurobindo Pharma Ltd. key Products/Revenue Segments include Pharmaceuticals, Sale of services, Export Incentives and Scrap for the year ending 31-Mar-2024.

Pursuant to Regulation 30 of SEBI Listing Regulations, and further to our letter dated August 5, 2024, please note that the audio recording of the earnings call on the Unaudited Financial Results for the first quarter ended June 30, 2024, held on August 12, 2024, at 8.30 AM (IST), has been uploaded on our website on the following web-link:https://www.aurobindo.com/investors/disclosures-under-regulation-46/investor-meet/audio-or-video-recordings

Submission of unaudited financial results for the quarter ended June 30, 2024, published in newspapers.

Revenue from operations increased to Rs 7,567 crore in the June quarter as against Rs 6,851 crore in the year-ago period, the drug maker said in a statement.

Aurobindo Pharma Ltd has surged about 30% over the past 3 months, hitting a new record high. The momentum continued into August. Experts recommend short- to medium-term traders consider buying the stock with a target of Rs 1,580 in the next 3-4 weeks. The stock rose from Rs 1,124 on May 7, 2023, to Rs 1,465 on August 7, 2024, reflecting a 30% gain in just 3 months.

Intimation of loss of share certificate informed by the shareholder.

Please find attached the Press Release that is being issued by the Company in connection with USFDA approval Estradiol Vaginal Inserts USP 10 mcg.

Please find attached copies of notice published in newspapers intimating the shareholders about dispatch of AGM Notice and Annual Report for the financial year 2023-24

Please find attached BRSR for the financial year 2023-24.

Please find attached Notice of 37th Annual General Meeting of the Company to be held on August 29, ,2024 at 3.30 P.M (IST).

Please find attached Annual Report of the Company for the financial year 2023-24.

Intimation of classification of US FDA inspection of Unit II of Eugia Pharma Specialities Limited, a wholly owned subsidiary of the Company.

Intimation of earnings call for the first quarter ended June 30, 2024 to be held on August 12, 2024 at 8.30 A.M.

Submission of Letter of Offer for Buyback of equity shares of the Company.

Companies such as Welspun Living and Aurobindo Pharma have already announced share buybacks, while AIA Engineering, Savita Oil Technologies, and Cera Sanitaryware are scheduled to hold board meetings to consider similar actions.

Enclosing the copies of notice published in the newspapers, Business Standard and Nava Telangana on July 31, 2024.

AUROBINDO PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2024 ,inter alia, to consider and approve Intimation of Board Meeting to be held on August 10, 2024 to consider and approve, interalia, the financial results for the first quarter ended June 30, 2024.

Intimation of Book closure for the Annual General Meeting to be held on Thursday, August 29, 2024.

Intimation of holding of 37th Annual General Meeting of the Company on Thursday, August, 29, 2024.

Submission of Public Announcement published in the newspapers announcing Buyback of shares of the Company through tender route.

Aurobindo Pharma announced on Thursday that its board has approved a buyback of 51.37 lakh shares at Rs 1,460 per share, marking a 6.4% premium over Tuesday's closing price. The record date for the Rs 750 crore share buyback scheme, conducted via the tender offer route, is set for July 30.

The Company has fixed Tuesday, July 30, 2024 as the Record Date for Buyback of equity shares of the Company.